Edition:
United Kingdom

Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

5.96USD
6:12pm GMT
Change (% chg)

$-0.29 (-4.64%)
Prev Close
$6.25
Open
$6.16
Day's High
$6.16
Day's Low
$5.60
Volume
3,207
Avg. Vol
6,773
52-wk High
$15.15
52-wk Low
$5.01

Latest Key Developments (Source: Significant Developments)

Aravive Qtrly Loss Per Share $1.08
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Aravive Inc ::ARAVIVE INC QTRLY LOSS PER SHARE $1.08.ARAVIVE INC - CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $62.6 MILLION AS OF SEPTEMBER 30, 2018.  Full Article

Versartis Q4 Earnings Per Share $0.87
Thursday, 1 Mar 2018 

March 1 (Reuters) - Versartis Inc ::VERSARTIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 EARNINGS PER SHARE $0.87.‍CONTRACT REVENUE FOR QUARTER AND YEAR ENDED DECEMBER 31, 2017 WAS $40.0 MILLION​.  Full Article

Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis Inc
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Versartis Inc ::ADVENT LIFE SCIENCES LLP REPORTS A 4.5 PERCENT PASSIVE STAKE IN VERSARTIS, INC. AS OF DEC 31, 2017 - SEC FILING.  Full Article

Versartis reports Q3 loss $1.40/shr
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Versartis Inc :Versartis reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $1.40.Q3 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.  Full Article

Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint
Thursday, 21 Sep 2017 

Sept 21 (Reuters) - Versartis Inc :Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint.Versartis Inc - Study ‍did not meet its primary endpoint of non-inferiority.​.Versartis Inc says ‍somavaratan was well tolerated with treatment discontinuation rate lower than for genotropin arm.​.Versartis Inc - ‍No new emergent safety signals were observed in the study​.  Full Article

Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Versartis Inc :Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​.  Full Article

Versartis reports Q2 loss per share $1.04
Thursday, 27 Jul 2017 

July 27 (Reuters) - Versartis Inc :Versartis reports second quarter 2017 financial results.Q2 loss per share $1.04.Q2 earnings per share view $-0.84 -- Thomson Reuters I/B/E/S.  Full Article

Versartis Q1 loss per share $0.85
Thursday, 27 Apr 2017 

April 27 (Reuters) - Versartis Inc ::Versartis reports first quarter 2017 financial results.Q1 loss per share $0.85.Versartis Inc - research and development (research and development) expenses for quarter ended march 31, 2017 were $22.0 million, compared to $18.2 million.Q1 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.  Full Article

Versartis reports new data on Somavaratan in growth hormone deficiency
Monday, 3 Apr 2017 

Versartis Inc : Versartis reports new data on long-acting Somavaratan in growth hormone deficiency at endo 2017 . Baseline characteristics of phase 3 velocity trial population balanced between study arms and comparable to phase 2 .Further results from vital trial in adult ghd-similar Somavaratan PK/PD data in U.S., Japanese children support using same dose in ongoing phase 3 trials.  Full Article

Versartis Q4 loss per share $0.64
Tuesday, 21 Feb 2017 

Versartis Inc : Versartis reports fourth quarter 2016 financial results . Q4 loss per share $0.64 .Q4 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article